Products
Polatuzumab Vedotin Biosimilar Antibody-Drug Conjugate (CD79B) for Research
Pre-made Polatuzumab Vedotin benchmark antibody (Whole mAb ADC, anti-CD79B therapeutic antibody, Anti-AGM6/B29/IGB Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-962-1mg | 1mg | 4635 |
| GMP-Bios-INN-962-10mg | 10mg | |
| GMP-Bios-INN-962-100mg | 100mg | |
| GMP-Bios-INN-962-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Polatuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Cd79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody Drug Conjugate |
| INN Name | Polatuzumab Vedotin |
| Target | CD79B |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - CD79B
1. Protein B-cell antigen receptor complex-associated protein beta chain
2. Gene CD79B
3. Organism Homo sapiens (Human)
Function
SRequired in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.
